Nanobiotix launches EUR 75 million global follow-on offering of shares, warrants

  • Nanobiotix launched a global follow-on offering targeting about EUR 75 million, split between a US public offering of ADSs and an international offering of ordinary shares and pre-funded warrants.
  • Jefferies, TD Cowen, Stifel to act as global coordinators and joint bookrunners.
  • Underwriters to receive a 30-day option to buy up to 15% additional ADSs on the same terms.
  • Pricing expected before the US market open on May 21, 2026; the ordinary share price in the international tranche to be set off the May 18-May 20 Euronext VWAP with up to a 15% discount.
  • Net proceeds earmarked mainly for Nanoprimer and other platforms, with smaller allocations for JNJ-1900 (NBTXR3) development, general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605201819PRIMZONEFULLFEED9724324) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.